Shane J. Schaffer, PharmD is the Founder of Cingulate Therapeutics and has served as CEO since its inception. Dr. Schaffer is a 30-year pharmaceutical industry veteran with experience in pharmaceutical drug development, commercialization, and biotech commercial operations. During his career, he has held positions at Pfizer, Novartis and Sanofi (including predecessor companies).
Dr. Schaffer has broad functional and therapeutic expertise through the development and commercialization of several billion- dollar brands including the ADHD Franchise of Ritalin® & Focalin®, Lipitor®, Lyrica®, Eligard®, Arixtra®, Hyalgan® and Avapro®/Avalide®. He has led the strategic brand planning, franchise resource allocation and managed care & reimbursement strategy for numerous products.
As CEO of Cingulate, Dr. Schaffer has brought in more than $160 million in capital investments, spearheaded the development the Precision Timed Release® drug delivery platform, built a drug development and commercialization organization, and is embarking on a first in industry precision-orchestrated, AI-enabled launch that delivers big-pharma commercial capability with ROI driven capital discipline—investing behind proof, scaling behind performance.
Dr. Schaffer received his Doctor of Pharmacy degree from the University of Kansas. He served as Chief Fellow and completed a Post-Doctoral Pharmaceutical Industry Fellowship at Rutgers University, College of Pharmacy in conjunction with Warner-Lambert/Parke-Davis, now Pfizer.
What is Shane J. Schaffer's net worth?
The estimated net worth of Shane J. Schaffer is at least $52.86 thousand as of February 6th, 2026. Dr. Schaffer owns 10,175 shares of Cingulate stock worth more than $52,859 as of September 18th. This net worth approximation does not reflect any other investments that Dr. Schaffer may own. Learn More about Shane J. Schaffer's net worth.
How do I contact Shane J. Schaffer?
Has Shane J. Schaffer been buying or selling shares of Cingulate?
Shane J. Schaffer has not been actively trading shares of Cingulate in the last ninety days. Most recently, on Friday, February 6th, Shane J. Schaffer bought 6,809 shares of Cingulate stock. The stock was acquired at an average cost of $5.04 per share, with a total value of $34,317.36. Following the completion of the transaction, the chief executive officer now directly owns 10,175 shares of the company's stock, valued at $51,282. Learn More on Shane J. Schaffer's trading history.
Who are Cingulate's active insiders?
Are insiders buying or selling shares of Cingulate?
In the last year, Cingulate insiders bought shares 5 times. They purchased a total of 130,350 shares worth more than $656,964.00. The most recent insider tranaction occured on February, 13th when Director Thomas Jeffrey Hargroves bought 97,276 shares worth more than $490,271.04. Insiders at Cingulate own 5.3% of the company.
Learn More about insider trades at Cingulate. Information on this page was last updated on 2/13/2026.
